Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 18/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 18/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 5/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12651706 | 0.86 | ADORA2A (0.75) | ADORA2AADORA1ADORA3ADORA2BRAB9A | |
| SCHEMBL3678085 | 0.78 | ADORA1 (0.64) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL3679573 | 0.76 | ADORA1 (1.00) | ADORA2AADORA1ADORA3ADORA2BRAB9A | |
| SCHEMBL3684455 | 0.76 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL3677518 | 0.76 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL3673669 | 0.76 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL3674131 | 0.76 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL4711353 | 0.74 | ADORA2A (0.58) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL17297731 | 0.74 | ADORA2A (0.58) | ADORA2AADORA1ADORA3ADORA2BRAB9A | |
| SCHEMBL3674942 | 0.73 | ADORA2A (0.65) | ADORA2AADORA1ADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349861-B1 | THIENO(3,2-d)PYRIMIDINES AND FURANO(3,2-d)PYRIMIDINES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2008-09-10 | — | — | EP | claimed |
| US-7384949-B2 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2008-06-10 | — | — | US | claimed |
| US-20040097524-A1 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyimidines and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2004-05-20 | — | — | US | claimed |
| US-11413324-B2 | Compositions and methods for treating peripheral nerve disease, disorders, and injuries | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-08-16 | — | — | US | disclosed |
| US-11246871-B2 | Targeting adenosine A2A receptors for the treatment of levodopa-induced dyskinesias | NORTHWESTERN UNIVERSITY (US) | 2022-02-15 | — | — | US | disclosed |
| US-20200345725-A1 | Methods and Compositions for Treating Cancer | OMEROS CORPORATOIN | 2020-11-05 | — | — | US | disclosed |
| US-20200316074-A1 | TARGETING ADENOSINE A2A RECEPTORS FOR THE TREATMENT OF LEVODOPA-INDUCED DYSKINESIAS | NORTHWESTERN UNIVERSITY | 2020-10-08 | — | — | US | disclosed |
| WO-2018170359-A1 | COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL NERVE DISEASE, DISORDERS, AND INJURIES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2018-09-20 | — | — | WO | disclosed |
| EP-2564871-B1 | Therapeutic Agent for Migraine | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-11-15 | — | — | EP | disclosed |
| US-9254283-B2 | Therapeutic agent for migraine | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-02-09 | — | — | US | disclosed |
| US-8865731-B2 | Inhibitor of analgesic tolerance | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-10-21 | — | — | US | disclosed |
| EP-1949903-A2 | COMPOUNDS FOR THE TREATMENT OF AURICULAR FIBRILLATION | Proyecto de Biomedicina Cima, S.L. (ES) | 2008-07-30 | — | — | EP | disclosed |
| US-20080153820-A1 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyramidines and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2008-06-26 | — | — | US | disclosed |
| US-20080153820-A1 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyramidines and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2008-06-26 | — | — | US | disclosed |
| US-20080153820-A1 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyramidines and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2008-06-26 | — | — | US | disclosed |
| US-7384949-B2 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
| US-7384949-B2 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
| US-7384949-B2 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
| WO-2007045705-A2 | COMPOUNDS FOR THE TREATMENT OF AURICULAR FIBRILLATION | PROYECTO DE BIOMEDICINA CIMA, S.L. (ES) | 2007-04-26 | — | — | WO | disclosed |
| US-20040097524-A1 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyimidines and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200316074-A1 | TARGETING ADENOSINE A2A RECEPTORS FOR THE TREATMENT OF LEVODOPA-INDUCED DYSKINESIAS | ADORA2A, PARK7, ADORA3 | ADORA2A 1/4885ADORA1 6/4885ADORA3 3/4885 |
| US-20040097524-A1 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyimidines and their use as purinergic receptor antagonists | CNR1, CNR2, RYR2 | ADORA2A 26/4885ADORA1 67/4885ADORA3 70/4885 |
| US-20200345725-A1 | Methods and Compositions for Treating Cancer | LPAR5, LPAR3, LPAR1 | ADORA2A 133/4885ADORA1 792/4885ADORA3 823/4885 |
| US-11413324-B2 | Compositions and methods for treating peripheral nerve disease, disorders, and injuries | GAP43, EPHA4, EPHA3 | ADORA2A 27/4885ADORA1 59/4885ADORA3 25/4885 |
| US-11246871-B2 | Targeting adenosine A2A receptors for the treatment of levodopa-induced dyskinesias | ADORA2A, PARK7, ADORA3 | ADORA2A 1/4885ADORA1 6/4885ADORA3 3/4885 |
| US-20080153820-A1 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyramidines and their use as purinergic receptor antagonists | CHRNA5, HTR5A, CHRNA6 | ADORA2A 6/4885ADORA1 37/4885ADORA3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.